Natural Capsules Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Capsules Limited reported FY2025-26 standalone revenue of Rs 18,142 Lakhs, up 5.4% from Rs 17,217 Lakhs in the previous year. Net profit surged 67% to Rs 1,121.39 Lakhs from Rs 671.11 Lakhs, driven by improved operational efficiency. Basic EPS increased from Rs 6.43 to Rs 10.79. Consolidated net profit attributable to shareholders was Rs 1,707.36 Lakhs (vs Rs 617.78 Lakhs), with consolidated EPS of Rs 16.48. The Board also approved re-appointment of Whole-time Director Mr. Laxminarayan Moondra, appointment of new Company Secretary Mr. Akshay Dutta, and internal auditor M/s Mallya & Mallya. Additionally, 25,000 equity shares were allotted under ESOP 2025, increasing paid-up capital to Rs 10.41 Crore. Statutory auditors P. Chandrasekar LLP issued an unmodified (clean) opinion on the financial statements.
Strong profit growth of 67% YoY is positive for shareholders and signals operational efficiency improvements. The clean audit opinion removes concerns about financial reporting quality. ESOP allotment and management changes suggest normal corporate governance activity.